Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Genzyme, Isis Say Cholesterol Drug Meets Goals

By Pharmaceutical Processing | August 4, 2010

NEW YORK (AP) — Genzyme Corp. and Isis Pharmaceuticals Inc. said today their cholesterol drug candidate mipomersen met key goals in two late-stage studies.

The companies said mipomersen reduced LDL-C, or total cholesterol, by 36 percent in patients with severe high cholesterol, or hypercholesterolemia, compared with a 13 percent reduction for patients taking placebo. Meanwhile, the drug prompted a 37 percent reduction in total cholesterol for patients with high cholesterol at high cardiovascular risk, compared with 5 percent taking placebo.

Both studies met all their secondary endpoints, and frequently observed side effects included injection site reactions, flu-like symptoms, and elevations in liver enzymes.

The results come months after positive results from a study focusing on patients with a genetic disorder, called heterozygous familial hypercholesterolemia, that raises “bad” cholesterol. At that time in February, the company said it wanted to finish other studies and get the drug on the market before it seeks approval for that illness. One such condition includes homozygous familial hypercholesterolemia, which is rarer than the heterozygous form.

Overall, it has now completed four late-stage studies on the drug for various types of cholesterol conditions. It expects to start seeking Food and Drug Administration approvals during the first half of 2011.

Mipomersen was discovered by Isis, of Carlsbad, Calif., and licensed to Genzyme, which is based in Cambridge, Mass.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE